Judgment of the General Court of 22 January 2015 — Teva Pharma and Teva Pharmaceuticals Europe v EMA
(Case T-140/12) 1
(Medicinal products for human use — Orphan medicinal products — Application for marketing authorisation for the generic version of the orphan medicinal product imatinib — EMA decision refusing to validate the application for marketing authorisation — Market exclusivity)
Language of the case: English
Parties
Applicants: Teva Pharma BV (Utrecht, Netherlands); and Teva Pharmaceuticals Europe BV (Utrecht) (represented by: D. Anderson, QC, K. Bacon, Barrister, G. Morgan and C. Drew, Solicitors)Defendant: European Medicines Agency (EMA) (represented by: T. Jabłoński, M. Tovar Gomis and N. Rampal
orisation — Market exclusivity)Language of the case: EnglishPartiesApplicants: Teva Pharma BV (Utrecht, Netherlands); and Teva
Pharmaceuticals Europe BV (Utrecht) (represented by: D. Anderson, QC, K. Bacon,
conc
erns therapeutic indications for the treatment of chronic myeloid leukaemia.Operative part of the judgmentThe Court:Dismisses the action.Orders TEVA Pharma BV and Teva Pharmaceuticals Europe BV to bear their own costs and to pay the costs incurred by the European Medicines Agency (EMA).Orders the European Commission to bear it
s own costs.
________________________1 OJ C 165, 9.6.20